SAN FRANCISCO – Opening his presentation during the J.P. Morgan Healthcare Conference Wednesday morning, Hospira Inc. CEO Michael Ball zipped through updates on the firm's injectable and device businesses and focused the majority of his talk on the firm's efforts in biosimilars, a space that finally appears to be opening up in the U.S.